A Single-Centre Cohort Study to Investigate Determinants and Outcomes of the Choice to Switch to Dolutegravir within Different Three or Two drug Regimens

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Atazanavir (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Emtricitabine/tenofovir (Primary) ; Lamivudine (Primary) ; Rilpivirine (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms DOLUTILITY

28 Dec 2018 New trial record
31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com